At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 12 enrolled

Drug / intervention

Doxycyclinedrug

Likely dose

Doxycycline 100 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02775695

NCT02775695Phase 2Completed

Compare CT.gov

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

Medical College of Wisconsin·interventional·Posted May 18, 2016·Updated Jul 3, 2023

In Brief

A Phase 2 clinical trial evaluating Doxycycline for Resectable Pancreatic Cancer. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This is a window-of-opportunity study that examines the efficacy of doxycycline, and FDA-approved oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic cancer following eight weeks of treatment.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsResectable Pancreatic Cancer

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedMay 2016

Enrollment StartApr 2017

Primary CompletionSep 2018

Study CompletionMay 2022

TodayJul 2026

First PostedMay 18, 2016

Enrollment StartApr 3, 2017

Primary CompletionSep 25, 2018

Study CompletionMay 26, 2022

TodayJul 2, 2026

Enrollment to primary: 1.5 yearsPosted 10.1 years ago

Interventions

Doxycyclinedrug

Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.